敏感的HLA抗体测试和抗体中介排斥和移植失败的风险
Tim Debyser1, Jasper Callemeyn1, Maarten Coemans1
1Department of Microbiology, Immunology and Transplantation, Nephrology and Kidney Transplantation Research Group, KU Leuven, Leuven, Belgium.
HLA
|June 27, 2024
概括
在脏移植中过渡到Luminex HLA测试减少了抗体介导排斥 (AMR). 虽然Luminex测试发现了更少的移植前捐赠者特异性抗体 (DSA),但它并没有改善整体移植存活率,强调需要平衡敏感性和器官可用性.
科学领域:
- 免疫学 免疫学 免疫学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 移植科学 移植科学
背景情况:
- 在移植中,对HLA抗体的固体相检测至关重要.
- 单抗原珠 (Luminex®) 试验的灵敏度比酶相关免疫吸收试验 (ELISA) 高.
- 测试方法的转变影响临床结果和患者管理.
研究的目的:
- 评估敏感的HLA测试对抗体介导排斥 (AMR) 和异种移植存活率的影响.
- 为了比较在采用基于Luminex的HLA测试之前和之后的结果.
- 评估Luminex敏感性在移植中的临床实用性.
主要方法:
- 对1818名在2004年3月至2021年5月间移植的移植受体进行了回顾性分析.
- 对ELISA时代 (2008年之前) 和Luminex时代 (2008年之后) 的移植进行比较.
- 使用Luminex测试对ELISA时代样本进行回顾性测试.
主要成果:
- 与ELISA时代 (48%) 相比,在Luminex时代 (28%) 检测到的移植前供体特异性抗体 (DSA) 显著减少.
- 基于Luminex的测试的实施与AMR发生率的显著下降有关 (p=0.003).
- 在两个测试时代之间,移植失败的发生率没有显著差异.
结论:
- 卢米内克斯HLA测试可以识别更少的移植前DSA患者,从而有可能预防低风险的AMR病例.
- 过渡到Luminex测试显著降低了移植后的AMR.
- 需要平衡Luminex测试的高灵敏度与器官等待时间,以优化移植结果.
更多相关视频
相关概念视频
Cell-mediated Immune Responses
68.1K
Overview
68.1K
Tissue Transplantation
356
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
356
Bone Marrow Sampling and Transplants
324
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
324
Blood Transfusion and Agglutination
10.8K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
10.8K


